Literature DB >> 18506007

Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice.

Daisuke Fujioka1, Yukio Saito, Tsuyoshi Kobayashi, Toshiaki Yano, Hideo Tezuka, Yoshikazu Ishimoto, Noriko Suzuki, Yasunori Yokota, Takamitsu Nakamura, Jyun-ei Obata, Masaki Kanazawa, Ken-ichi Kawabata, Kohji Hanasaki, Kiyotaka Kugiyama.   

Abstract

BACKGROUND: Group X secretory phospholipase A(2) (sPLA(2)-X) has the most potent hydrolyzing activity toward phosphatidylcholine and elicits a marked release of arachidonic acid among several types of sPLA(2). sPLA(2)-X is expressed in neutrophils, but its pathogenic role remains unclear. METHODS AND
RESULTS: We generated mice that lack sPLA(2)-X and studied their response to myocardial ischemia/reperfusion. The sPLA(2)-X(-/-) mice had a significant reduction in myocardial infarct size and a decrease in myocardial myeloperoxidase activity compared with sPLA(2)-X(+/+) mice. Myocardial infarct size was also significantly reduced in lethally irradiated sPLA(2)-X(+/+) mice reconstituted with sPLA(2)-X(-/-) bone marrow compared with sPLA(2)-X(+/+) bone marrow. The extent of myocardial ischemia/reperfusion injury was comparable between sPLA(2)-X(-/-) and sPLA(2)-X(+/+) mice in Langendorff experiments using isolated hearts and blood-free perfusion buffer, supporting a potential role of sPLA(2)-X in blood in myocardial ischemia/reperfusion injury. In the infarcted myocardium of sPLA(2)-X(+/+) mice, sPLA(2)-X was released from neutrophils but not myocardial tissues and platelets and was undetectable in the peripheral serum. The sPLA(2)-X(-/-) mice had lower accumulation of neutrophils in ischemic myocardium, and the isolated sPLA(2)-X(-/-) neutrophils had lower release of arachidonic acid and attenuated cytotoxic activities including respiratory burst compared with sPLA(2)-X(+/+) neutrophils. The attenuated functions of sPLA(2)-X(-/-) neutrophils were reversible by the exogenous addition of sPLA(2)-X protein. Furthermore, administration of a sPLA(2) inhibitor reduced myocardial infarct size and suppressed the cytotoxic activity of sPLA(2)-X(+/+) neutrophils.
CONCLUSIONS: Myocardial ischemia/reperfusion injury was attenuated in sPLA(2)-X(-/-) mice partly through the suppression of neutrophil cytotoxic activities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18506007     DOI: 10.1161/CIRCULATIONAHA.107.743997

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  27 in total

1.  Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.

Authors:  Hiroyasu Sato; Rina Kato; Yuki Isogai; Go-ichi Saka; Mitsuhiro Ohtsuki; Yoshitaka Taketomi; Kei Yamamoto; Kae Tsutsumi; Joe Yamada; Seiko Masuda; Yukio Ishikawa; Toshiharu Ishii; Tetsuyuki Kobayashi; Kazutaka Ikeda; Ryo Taguchi; Shinji Hatakeyama; Shuntaro Hara; Ichiro Kudo; Hiroyuki Itabe; Makoto Murakami
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

2.  Group X secretory phospholipase A2 enhances TLR4 signaling in macrophages.

Authors:  Preetha Shridas; William M Bailey; Kayla R Talbott; Rob C Oslund; Michael H Gelb; Nancy R Webb
Journal:  J Immunol       Date:  2011-05-27       Impact factor: 5.422

3.  Cytosolic phospholipase A(2)α protects against ischemia/reperfusion injury in the heart.

Authors:  Risto Kerkelä; Matthieu Boucher; Raihana Zaka; Erhe Gao; David Harris; Jarkko Piuhola; Jianliang Song; Raisa Serpi; Kathleen C Woulfe; Joseph Y Cheung; Eileen O'Leary; Joseph V Bonventre; Thomas Force
Journal:  Clin Transl Sci       Date:  2011-08       Impact factor: 4.689

4.  Disruption of group IVA cytosolic phospholipase A(2) attenuates myocardial ischemia-reperfusion injury partly through inhibition of TNF-α-mediated pathway.

Authors:  Yukio Saito; Kazuhiro Watanabe; Daisuke Fujioka; Takamitsu Nakamura; Jun-ei Obata; Kenichi Kawabata; Yosuke Watanabe; Hideto Mishina; Shun Tamaru; Yoshihiro Kita; Takao Shimizu; Kiyotaka Kugiyama
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-16       Impact factor: 4.733

5.  Acute coronary syndromes: targeting inflammation-what has the VISTA-16 trial taught us?

Authors:  Michelle L O'Donoghue
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

6.  Ectopically expressed pro-group X secretory phospholipase A2 is proteolytically activated in mouse adrenal cells by furin-like proprotein convertases: implications for the regulation of adrenal steroidogenesis.

Authors:  Joseph D Layne; Preetha Shridas; Nancy R Webb
Journal:  J Biol Chem       Date:  2015-01-26       Impact factor: 5.157

7.  Group X phospholipase A2 is released during sperm acrosome reaction and controls fertility outcome in mice.

Authors:  Jessica Escoffier; Ikram Jemel; Akemi Tanemoto; Yoshitaka Taketomi; Christine Payre; Christelle Coatrieux; Hiroyasu Sato; Kei Yamamoto; Seiko Masuda; Karin Pernet-Gallay; Virginie Pierre; Shuntaro Hara; Makoto Murakami; Michel De Waard; Gérard Lambeau; Christophe Arnoult
Journal:  J Clin Invest       Date:  2010-04-26       Impact factor: 14.808

8.  Group X secretory phospholipase A2 regulates the expression of steroidogenic acute regulatory protein (StAR) in mouse adrenal glands.

Authors:  Preetha Shridas; William M Bailey; Boris B Boyanovsky; Rob C Oslund; Michael H Gelb; Nancy R Webb
Journal:  J Biol Chem       Date:  2010-04-26       Impact factor: 5.157

9.  Group III secreted phospholipase A2 transgenic mice spontaneously develop inflammation.

Authors:  Hiroyasu Sato; Yoshitaka Taketomi; Yuki Isogai; Seiko Masuda; Tetsuyuki Kobayashi; Kei Yamamoto; Makoto Murakami
Journal:  Biochem J       Date:  2009-06-12       Impact factor: 3.857

10.  Molecular and functional characterization of polymorphisms in the secreted phospholipase A2 group X gene: relevance to coronary artery disease.

Authors:  Sarah Gora; Claire Perret; Ikram Jemel; Viviane Nicaud; Gérard Lambeau; François Cambien; Ewa Ninio; Stefan Blankenberg; Laurence Tiret; Sonia-Athina Karabina
Journal:  J Mol Med (Berl)       Date:  2009-06-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.